Block listing Interim Review

RNS Number : 0479Q

AstraZeneca PLC

01 June 2018

 

01 June 2018 15:00 BST

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 1 June 2018

Name of applicant:		ASTRAZENECA PLC
Name of scheme:		ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME
Period of return:	From:	1 December 2017	To:	31 May 2018
Balance of unallotted securities under scheme(s) from previous return:		2,657,192
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		665,884
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1,991,308

Name of contact:	CAMILLA WISEMAN
Telephone number of contact:	020 3749 5000

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Gonzalo Viña	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Matt Kent	UK/Global	[phone]
Karen Birmingham	UK/Global	[phone]
Jacob Lund	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Josie Afolabi		[phone]
Craig Marks	Finance; Fixed Income; M&A	[phone]
Henry Wheeler	Oncology	[phone]
Mitchell Chan	Oncology; Other	[phone]
Christer Gruvris	Brilinta; Diabetes	[phone]
Nick Stone	Respiratory; Renal	[phone]
Jennifer Kretzmann	Retail investors	[phone]
US toll free		[phone]

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

END

 

 

BLRSSIFFFFASEFM